Payment overview · 2025
General Payments
$723.41
43 reported records · 18 companies
Healthcare provider profile · identity verified
Yun-Wei Chang
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · MILTON, FL · NPI 1255708459
Verified facts
What the public records show
CMS Open Payments records show Yun-Wei Chang received $723.41 in general payments during 2025 across 43 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $134.87 | 18.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.99 | 14.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.38 | 11.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.50 | 7.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.99 | 6.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.69 | 5.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.40 | 5.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.30 | 4.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.16 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.95 | 3.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.37 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.6% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $18.02 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.47 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.99 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.66 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.45 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $723.41 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $164.17 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.68 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.85 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.69 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.14 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 170 | 50 |
| Lisinopril | Lisinopril | 162 | 65 |
| Omeprazole | Omeprazole | 156 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 97 | 49 |
| Famotidine | Famotidine | 96 | 39 |
| Fluconazole | Fluconazole | 96 | 53 |
| Potassium Chloride | Potassium Chloride | 96 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 30 |
| Baclofen | Baclofen | 91 | 33 |
| Promethazine Hcl | Promethazine Hcl | 88 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 34 |
| Prednisone | Prednisone | 84 | 62 |
| Montelukast Sodium | Montelukast Sodium | 83 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 72 | 36 |
| Celecoxib | Celecoxib | 72 | 24 |
| Trazodone Hcl | Trazodone Hcl | 72 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 69 | 30 |
| Furosemide | Furosemide | 65 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 26 |
| Losartan Potassium | Losartan Potassium | 60 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 24 |
| Farxiga | Dapagliflozin Propanediol | 54 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 21 |
| Cephalexin | Cephalexin | 51 | 37 |
| Sertraline Hcl | Sertraline Hcl | 50 | 17 |
| Meloxicam | Meloxicam | 48 | 21 |
| Mounjaro | Tirzepatide | 48 | 16 |
| Ondansetron Odt | Ondansetron | 48 | 25 |
| Doxepin Hcl | Doxepin Hcl | 47 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 19 |
| Rybelsus | Semaglutide | 46 | 17 |
| Linzess | Linaclotide | 43 | 16 |
| Metformin Hcl | Metformin Hcl | 43 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 19 |
| Eliquis | Apixaban | 41 | 15 |
| Carvedilol | Carvedilol | 40 | 22 |
| Lactulose | Lactulose | 40 | 22 |
| Mupirocin | Mupirocin | 39 | 27 |
| Ozempic | Semaglutide | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Finasteride | Finasteride | 35 | 13 |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | 15 |
| Alendronate Sodium | Alendronate Sodium | 30 | 15 |
| Allopurinol | Allopurinol | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 29 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Clonidine Hcl | Clonidine Hcl | 28 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | 12 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | 11 |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $723.41 · 43 records | Otsuka America Pharmaceutical, Inc. | ACCRUFER, AIRSUPRA, AUSTEDO XR, CAPLYTA, CARTO 3, CREON, Dexcom G6 Transmitter, GEMTESA, GVOKE HYPOPEN, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error